{"name":"NeuroTrauma Sciences, LLC","slug":"neurotrauma-sciences-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NTS-104 TRIS","genericName":"NTS-104 TRIS","slug":"nts-104-tris","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"NTS-104 TRIS","genericName":"NTS-104 TRIS","slug":"nts-104-tris","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQOWlVV1o0dkdTOUFQSHVGLWVJSl9aZ2psa1FqSGtYNG45Uy1SRFJTUmpmcmJYck9rVUwwd1hxbndFdXpCallEZDFOQXhsRFdtTjlGeDBqTG5VZzd5UVNHTm5uSlY5eW96UUxUdHE2WWNhdnc0VWZaLXpFZldyVF9DWGRSblpxcUVqWjVNSHRQcGNqMG1jRTNXcWg0bU0yZDc4d3NxVE1ZdUpGOHBJS05TQ2RIMA?oc=5","date":"2023-07-31","type":"pipeline","source":"citybiz","summary":"NeuroTrauma Sciences Appoints Kevin Pong, PhD, MBA As Chief Business Officer - citybiz","headline":"NeuroTrauma Sciences Appoints Kevin Pong, PhD, MBA As Chief Business Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxNVGU3OWZKeE9memNGZmk0Tm9yQjI3SzlsZndUQWNudFE5d1BQU096TGZKSWRjNE9RaDdac0k5R25VajY1dW5hNU1TSUdxbmFTT3p1ckQ3N0hDZ2loR3JLREQxQ1FOVC1qLXJRZU9lYzZhMGJMYlJBQnhrMDlvUkJ4YjB5ZklPWTZLZlI5T0Zxd19rQUdfbk40ejhHM3UwLXdJR2N0THMxU25PMjF5RDBkMEJQNThOekRyUE9MN1ZSZXlTOWNXMHNFVzgwOG9EZ3hXeHB0OTBHdks3aF9mcjJJM0hsY1pBc2dJWW1QNDUtd2tNS1dUZlpQMXp3?oc=5","date":"2023-06-01","type":"pipeline","source":"PR Newswire","summary":"NeuroTrauma Sciences Commences First-in-Human Dosing in the US of Investigational Neuroprotective Drug NTS-104 - PR Newswire","headline":"NeuroTrauma Sciences Commences First-in-Human Dosing in the US of Investigational Neuroprotective Drug NTS-104","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNd2RnM2xFZGRzemRHRTNjTjlIQ2dacjlydS00UFJxNHNISjBuME12R0ZRX2RPR1F0V2lqallfZGstcy12blY0ZEFuRUlzLXJhNWRQMjI3OXFhWktUNDJyZUZzYk1LZTRocTVrM3d4Q0dJMUZ2QUp6OXF1anE5d1Y1bV9kYk9aMnNzU0VnS01lQlBSaE9LdFMyZFpNdVBJejN6Tkx1YU1R?oc=5","date":"2019-12-12","type":"pipeline","source":"BioWorld News","summary":"Neurotrauma Sciences exercises an option with Emory University - BioWorld News","headline":"Neurotrauma Sciences exercises an option with Emory University","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}